Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Relapsed DLBCL
NCT00097929Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2005
- Primary completion
- Jul 2006
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
A Phase 2 trial of vorinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Merck & Co.. Started May 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00097929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097929.